<div id="readability-page-1"><p>Barclays assumed coverage on shares of <span>ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report)</span> in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set an &#34;overweight&#34; rating and a $100.00 price target on the specialty pharmaceutical company's stock. Barclays's price target would indicate a potential upside of 20.90% from the stock's previous close.</p><p>Several other equities research analysts have also issued reports on the stock. HC Wainwright raised their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, September 17th. Truist Financial boosted their price target on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a &#34;hold&#34; rating in a report on Thursday, October 9th. Weiss Ratings  reissued a &#34;buy (b-)&#34; rating on shares of ANI Pharmaceuticals in a research note on Monday, December 1st. Wall Street Zen raised ANI Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, August 16th. Finally, Zacks Research raised ANI Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned  a Buy rating and one  has issued  a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $99.38.</p><div><p><span></span><span>Get <strong>ANI Pharmaceuticals</strong> alerts:</span></p></div><p><b>Check Out Our Latest Analysis on ANIP</b></p><h2>ANI Pharmaceuticals Stock Performance</h2><p>NASDAQ:ANIP traded up $1.37 during mid-day trading on Tuesday, hitting $82.71. 45,984 shares of the company traded hands, compared to its average volume of 375,563. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The stock's fifty day moving average price is $88.29 and its 200-day moving average price is $80.19. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of 50.74 and a beta of 0.48. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $99.50. </p><p>ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.74 by $0.30. The company had revenue of $227.81 million for the quarter, compared to analysts' expectations of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. ANI Pharmaceuticals's revenue for the quarter was up 53.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS.  Research analysts anticipate that  ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year. </p><h2>Insider Activity</h2><p>In other news, SVP Chad Gassert sold 14,642 shares of the firm's stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total transaction of $1,304,162.94. Following the sale, the senior vice president directly owned 158,584 shares in the company, valued at $14,125,076.88. This trade represents a 8.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $98.04, for a total value of $98,040.00. Following the transaction, the senior vice president directly owned 60,186 shares of the company's stock, valued at approximately $5,900,635.44. The trade was a 1.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 25,579 shares of company stock valued at $2,271,691. Insiders own  12.70% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. purchased a new stake in shares of  ANI Pharmaceuticals in the first quarter valued at approximately $28,000.  Hantz Financial Services Inc. raised its stake in shares of  ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company's stock valued at $32,000 after acquiring an additional 237 shares during the period.  Caitong International Asset Management Co. Ltd boosted its position in shares of  ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company's stock worth $34,000 after buying an additional 510 shares during the period.  Newbridge Financial Services Group Inc. grew its position in  ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock valued at $39,000 after acquiring an additional 400 shares in the last quarter.  Finally, State of Wyoming purchased a new stake in  ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. 76.05% of the stock is owned by institutional investors and hedge funds. </p><h2>ANI Pharmaceuticals Company Profile</h2> (Get Free Report)<p>ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.</p><h2>Read More</h2><ul><li>Five stocks we like better than ANI Pharmaceuticals</li><li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li><li>Oil Prices May Fall to $55 by 2026—Bad News for This Energy ETF</li><li>What is diluted earnings per share (Diluted EPS)?</li><li>5 High Short-Interest Stocks to Buy Before Q1 2026</li><li>3 Stocks to Consider Buying in October</li><li>Why These 3 Automotive &amp; Industrial Chip Stocks Just Soared</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p><p>While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ANIP

<p>Barclays initiated coverage on ANI Pharmaceuticals with an "overweight" rating and a $100 target price, indicating a potential 20.90% upside. Other analysts have also issued positive ratings, with a consensus "Buy" rating and a $99.38 target. ANI Pharmaceuticals reported strong earnings, with a 53.6% revenue increase year-over-year. Insider trading activity includes significant stock sales by senior vice presidents. Institutional investors have adjusted their stakes in the company.</p>

ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at Barclays